09:21 AM EDT, 05/27/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said Tuesday that it has started preclinical "IND-enabling" studies for BD9, an experimental treatment for atopic dermatitis and asthma developed in partnership with Biolojic Design.

Teva said the investigational therapy, known as BD9, targets IL-13 and TSLP, two proteins associated with TH2-driven inflammation.

Teva has exclusive global development rights to the drug through a licensing agreement with Biolojic and Biolojic may receive milestone payments tied to BD9's progress through development and commercialization, Teva said.

Shares of Teva were up 2.7% in recent Tuesday premarket activity.